The Zacks Analyst Blog Highlights: Broadcom, Canadian National, CVS Health, Aflac And DXC Technolog

For Immediate Release

Chicago, IL – Feb 14, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Broadcom (NASDAQ:AVGO) , Canadian National (NYSE:CNI) , CVS Health (NYSE:CVS) , Aflac (NYSE:AFL) and DXC Technology (NYSE:DXC) .

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1Stock of the Day pick for free.

Here are highlights from Tuesday’s Analyst Blog:

Top Analyst Reports for Broadcom, Canadian National and CVS Health

The Zacks Research Daily presents the best research output of our analyst team. Today's Research Daily features new research reports on 16 major stocks, including Broadcom, Canadian National and CVS Health. These research reports have been hand-picked from the roughly 70 reports published by our analyst team today.

You can see all of today’s research reports here >>>

Buy-rated Broadcom’s shares have handily beaten the technology sector as well as the red-hot semiconductor space over the last one year, gaining +19%. Broadcom is benefiting from strong demand of its wireless solutions and expanding product portfolio, which makes it well-positioned to address the needs of rapidly growing technologies like IoT and 5G.

Broadcom has recently inked financing agreements with various institutions to fund Qualcomm’s proposed takeover. If completed, then this deal will make it the third-largest chipmaker, behind Intel (NASDAQ:INTC) and Samsung (KS:005930). The company also has strong ties with leading OEMs across multiple target markets that will help it to gain key insights into the requirements of customers.

Moreover, the upcoming launch of the next generation WiFi products is expected to be a growth driver for the segment. However, customer concentration, intensifying competition, integration risks due to frequent acquisitions and leverage balance sheet are key headwinds.

(You can read the full research report on Broadcom here >>>).

Shares of Canadian National have gained +7.4% over the last one year, but failed to outperform the Zacks Rail industry which gained +12.9% over the same period. Also, the company has underperformed Canadian Pacific Railway’s shares that have gained 17.6% in the same time period.

Adding to its woes, Canadian National reported lower-than-expected earnings per share and revenues in the fourth quarter of 2017. Deterioration in operating ratio owing to high labor and fuel costs also raise concerns. However, the volume growth witnessed in the quarter raises optimism.

The year-over-year increase in revenues and earnings per share bodes well for the stock as well. Moreover, the Zacks analyst is impressed by the 10% dividend hike announced by the company in January 2018.

(You can read the full research report on Canadian National here >>>).

CVS Health’s shares have been trading above the Zacks Drug Stores industry over the last year losing -11.2% vs. a decline of -16.7%. CVS Health ended the year 2017 on a solid note with a better-than-expected fourth-quarter performance.

The year-over-year growth in the top line was driven by a strong Pharmacy Services segment, benefiting from the upside in the specialty services. CVS Health’s strong 2018 PBM selling season is another upside. The Zacks analyst is also looking forward to an upbeat 2019 selling season.

Also, CVS Health’s plan to acquire Aetna (NYSE:AET) might change the Healthcare landscape in the United States. On the flip side, the company has been suffering from softness in Retail/LTC business and a weak margin scenario. However, year-over-year Retail/LTC comparisons were still unimpressive. A weak margin scenario continues to put pressure on the bottom line.

(You can read the full research report on CVS Health here >>>).

Other noteworthy reports we are featuring today include Aflac and DXC Technology.

Today, Zacks is promoting its ''Buy'' stock recommendations. Get #1 Stock of the Day pick for free.

About Zacks Equity Research

Zacks Equity Research provides the best of quantitative and qualitative analysis to help investors know what stocks to buy and which to sell for the long-term.

Continuous coverage is provided for a universe of 1,150 publicly traded stocks. Our analysts are organized by industry which gives them keen insights to developments that affect company profits and stock performance. Recommendations and target prices are six-month time horizons.

Strong Stocks that Should Be in the News

Many are little publicized and fly under the Wall Street radar. They're virtually unknown to the general public. Yet today's 220 Zacks Rank #1 "Strong Buys" were generated by the stock-picking system that has nearly tripled the market from 1988 through 2015. Its average gain has been a stellar +26% per year.See these high-potential stocks free >>.

Follow us on Twitter: https://twitter.com/zacksresearch

Join us on Facebook (NASDAQ:FB): https://www.facebook.com/home.php#/pages/Zacks-Investment-Research/57553657748?ref=ts

Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

Media Contact

Zacks Investment Research

800-767-3771 ext. 9339

support@zacks.com

https://www.zacks.com/

Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit https://www.zacks.com/performance for information about the performance numbers displayed in this press release.